Selexis SA: Launch of Generium's Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis' Ninth Commercial Product

Third Biosimilar to Reach the Market Under Selexis/Generium Commercial License Agreements Selexis SA and Generium JSC today announced that Genolar, Generium's biosimilar of omalizumab, is now commercially

Related Keywords

Russia ,Kulkov ,Arkhangel Skaya Oblast ,Russian ,Kostenloser Wertpapierhandel ,Selexis Generium ,Robert Meister ,Daniil Talyanskiy ,Vsevolod Letsko ,Roland Hecht ,Mike Beyer ,Instagram ,Linkedin ,Twitter ,Selexis Company Inquiries ,Sam Brown Inc ,Corporate Communications ,Facebook ,Life Sciences ,Business Development ,Third Biosimilar ,Market Under ,Generium Commercial License ,Selexis Genetic Elements ,Selexis ,Launch ,Generium ,Omalizumab ,Biosimilar ,Topic ,Bronchial ,Asthma ,Parks ,Ninth ,Commercial ,Product ,